OMNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Outset Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.80−0.14 (-3.55%)
Close on Oct 19, 2026
- Market cap
- $70.75K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2025
Gross margin
39.1%+65.2 pts over 5 years
Operating margin
-55.8%+179.4 pts over 5 years
Net margin
-68.3%+175.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +5.1% | +1.2% | +19.1% | – | |
| Gross profit | +21.2% | +37.9% | – | – |
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 557.6% | -106.2% | |
| Return on assets | – | -49.4% | -30.2% | |
| Current ratio | – | 9.43 | 6.67 | |
| Debt to equity | – | 0.10 | 0.76 | |
| Net debt to EBITDA | – | 2.30× | -0.98× | |
| Interest coverage | – | -40.6× | -4.8× | |
| Inventory turnover | – | 5.5× | 1.4× | |
| Capex to revenue | – | 18.2% | 0.7% | |
| Diluted shares | – | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Outset Medical generated $570.00M from operations and spent $16.58M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$570.00M
Used
$16.58M
Capital expenditure$16.58M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-68.3%
×Asset turnover0.44×
×Equity multiplier3.51×
=Return on equity, FY2025-106.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -68.3% | 0.44× | 3.51× | -106.2% |
| FY2024 | -112.6% | 0.39× | 3.94× | -171.0% |
| FY2023 | -132.5% | 0.37× | 1.94× | -93.7% |
| FY2022 | -141.2% | 0.27× | 1.39× | -52.6% |
| FY2021 | -128.6% | 0.24× | 1.23× | -37.6% |
| FY2020 | -243.3% | 0.20× | -11.29× | 557.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$81.65M
- Cash generatingOperating cash flow above zero-$46.33M
- Return on assets improvedROA up on the prior year-40.8% → -29.6%
- Earnings backed by cashOperating cash flow above net income-$46.33M vs -$81.65M
- Less leverageLong-term debt to assets fell71.6% → 36.4%
- Better liquidityCurrent ratio rose5.69 → 6.67
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year33.92% → 39.13%
- More efficientAsset turnover rose0.36 → 0.43